Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6VNS

Crystal structure of TYK2 kinase with compound 13

Summary for 6VNS
Entry DOI10.2210/pdb6vns/pdb
DescriptorNon-receptor tyrosine-protein kinase TYK2, (1R,2R)-2-cyano-N-[(1S,5R)-3-(5-fluoro-2-{[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]amino}pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]cyclopropane-1-carboxamide (3 entities in total)
Functional Keywordskinase, transferase, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight36962.99
Authors
Vajdos, F.F. (deposition date: 2020-01-29, release date: 2020-04-08, Last modification date: 2023-11-15)
Primary citationFensome, A.,Ambler, C.M.,Arnold, E.,Banker, M.E.,Clark, J.D.,Dowty, M.E.,Efremov, I.V.,Flick, A.,Gerstenberger, B.S.,Gifford, R.S.,Gopalsamy, A.,Hegen, M.,Jussif, J.,Limburg, D.C.,Lin, T.H.,Pierce, B.S.,Sharma, R.,Trujillo, J.I.,Vajdos, F.F.,Vincent, F.,Wan, Z.K.,Xing, L.,Yang, X.,Yang, X.
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Bioorg.Med.Chem., 28:115481-115481, 2020
Cited by
PubMed Abstract: Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.
PubMed: 32253095
DOI: 10.1016/j.bmc.2020.115481
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.09 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon